Arginase inhibitor and pharmaceutical composition comprising same
Novel pyrrolidine-based arginase inhibitors with unique structures address the limitations of existing compounds by effectively inhibiting arginase, restoring arginine levels, and enhancing cytotoxic T-cell activity for cancer treatment.
WO2026117031A1PCT designated stage Publication Date: 2026-06-04DAEWOONG PHARM CO LTD
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- DAEWOONG PHARM CO LTD
- Filing Date
- 2025-11-27
- Publication Date
- 2026-06-04
AI Technical Summary
Technical Problem
Current arginase inhibitors are limited by their chemical structures, and there is a need for compounds that can effectively inhibit arginase to restore arginine levels in the tumor microenvironment, enhancing the tumor-killing activity of cytotoxic T-cells for cancer treatment.
Method used
Development of novel pyrrolidine-based arginase inhibitors with unique chemical structures, represented by Chemical Formula 1, which inhibit arginase and restore arginine levels, promoting cytotoxic T-cell activity.
Benefits of technology
The novel compounds demonstrate excellent arginase inhibitory activity, effectively restoring arginine levels and enhancing tumor-killing activity of cytotoxic T-cells, providing a potential treatment or prevention strategy for various cancers.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure KR2025019938_04062026_PF_FP_ABST
Abstract
The present invention relates to a compound represented by chemical formula 1 below, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same may be effectively used for prevention or treatment of cancer or tumors. In chemical formula 1, R is as defined in the specification.
Need to check novelty before this filing date? Find Prior Art